Wedbush analyst Liana Moussatos reiterated a Buy rating on Albireo Pharma (ALBO – Research Report) today and set a price target of $84.00. The company's shares closed last Tuesday at $27.57. According to TipRanks.com, Moussatos has 0 stars on 0-5 stars ranking scale with an average return of -5.0% and a 32.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, BioMarin Pharmaceutical, and Pacira Pharmaceuticals. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Albireo Pharma with a $77.00 average price target, a 131.6% upside from current levels. In a report issued on February 23, H.C.
https://www.tipranks.com/news/blurbs/wedbush-reiterates-their-buy-rating-on-albireo-pharma-albo?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Jul 2022 bis Aug 2022 Click Here for more Albireo Pharma Charts.
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Aug 2021 bis Aug 2022 Click Here for more Albireo Pharma Charts.